Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company ...
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT), a commercial-stage biotechnology company with a market capitalization of $428 million specializing in mRNA therapeutics and vaccines, stands at a ...
Hosted on MSN13d
BTIG Initiates Coverage of Arcturus Therapeutics Holdings (ARCT) with Buy RecommendationFintel reports that on January 28, 2025, BTIG initiated coverage of Arcturus Therapeutics Holdings (NasdaqGM:ARCT) with a Buy ...
Spire Wealth Management increased its holdings in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT – Free Report) by 393.3% during the 4th quarter, according to its most recent Form 13F ...
In the assessment of 12-month price targets, analysts unveil insights for Arcturus Therapeutics, presenting an average target ...
Arcturus Therapeutics (ARCT) announced the appointment of Moncef Slaoui as chair designate. Slaoui has been serving on the company’s board of ...
SAN DIEGO--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of ...
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT), a commercial-stage biotechnology company with a market capitalization of $428 million specializing in mRNA therapeutics and vaccines, stands at a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback